Sandoz joins Accord in targeting US university

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Sandoz joins Accord in targeting US university

Viersen, Germany - May 9. 2020: Close up of mobile phone screen

The claim, filed this week against the University of California’s governing board, follows action by Accord Healthcare in October

Sandoz has become the second pharmaceutical company in the last few months to take action against the governing board of the University of California, according to a case filed with the England and Wales High Court on Tuesday, January 24.

The generics arm of Swiss outfit Novartis has filed pleadings against The Regents of the University of California. Publicly available documents are expected to be released in early February.

Sandoz filed the case in the patents division of the England and Wales High Court, but no further details are available at this stage.

The case follows action taken by Accord Healthcare in October last year in which the pharma company sought to invalidate a European patent and supplementary protection certificate (SPC) owned by the Regents.

That dispute arose after Accord signalled its intention to produce a capsule form of enzalutamide, a treatment for prostate cancer, in 2024 following the expiry of market exclusivity.

In the Accord case, the Regents first claimed that launching a capsule before the expiry date of a patent (EP 1,893,196) and SPC (GB13/079) it owns would amount to infringement.

In a counterclaim, Accord sought an order that the patent, called ‘diarylhydantoin compound’, is invalid and that the SPC is also invalid and should not come into force.

That case is expected to go to trial in the coming months. It is not known at this stage if the Sandoz dispute surrounds the same claims.

Bristows is representing Sandoz, whereas the Regents’ counsel have not been announced yet. In the Accord case, Pinsent Masons is acting for Accord while the Regents is being represented by Kirkland & Ellis.

more from across site and SHARED ros bottom lb

More from across our site

IP leaders at Brandsmiths and Bird & Bird, who were on opposing sides at the UK Supreme Court in Iconix v Dream Pairs, unpick the landmark case and its ramifications
Magdalena Bonde discusses Abion’s AI experiments and reveals why an entrepreneurial mindset and a willingness to learn about a business are essential skills
Partner Ginevra Righini explains how she secured victory for the Comité Champagne in its fight against an EUTM application for ‘Nero Champagne’
Volkan Hamamcıoğlu joins us for our ‘Five minutes with’ series to discuss meditation, tackling deadlines, and taking inspiration from Hamlet
A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Gift this article